{"id":4049,"date":"2026-11-02T09:00:00","date_gmt":"2026-11-02T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4049"},"modified":"2026-11-03T22:18:31","modified_gmt":"2026-11-04T02:18:31","slug":"ctx310-receives-two-fda-rmat-designations","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4049","title":{"rendered":"CTX310 Receives Two FDA RMAT Designations"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

CRISPR Therapeutics<\/p>\n

Event Type<\/strong><\/p>\n

Regulatory designation (RMAT) and Q3 update (source-gap recovery)<\/p>\n

Modality<\/strong><\/p>\n

In vivo LNP-delivered CRISPR liver editing<\/p>\n

Asset<\/strong><\/p>\n

CTX310<\/p>\n

Target<\/strong><\/p>\n

ANGPTL3<\/p>\n

Disease Area<\/strong><\/p>\n

Severe hypertriglyceridemia; elevated LDL-C<\/p>\n

Summary<\/h4>\n

In a November 2 disclosure recovered in the 36-hour window, CRISPR Therapeutics said FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310 for severe hypertriglyceridemia and elevated LDL-C. The company also reported third-quarter CASGEVY revenue of $99 million; earlier pediatric approvals were background, not new actions.<\/p>\n

CTX310 is an in vivo liver-directed edit of ANGPTL3. The company cited prior Phase 1a lipid reductions sustained to one year, but disclosed no new CTX310 efficacy dataset with the designation. Phase 1b data are scheduled for November 9; that notice is a future catalyst, not a readout.<\/p>\n

Deep Analysis<\/h4>\n

RMAT can facilitate FDA interaction and eligibility for expedited pathways; it does not establish efficacy, safety, or eventual approval. Inference A:<\/strong> designation may improve development alignment for a one-time editing approach in severe lipid disease, supported by the action and earlier biomarker durability. Counterpoint: cardiovascular outcome benefit and long-term editing risk are unproven. Inference B:<\/strong> the label has limited near-term strategic value without a robust indication-specific effect and risk profile; the absence of new data supports caution, while formal FDA engagement is still tangible. Next evidence: Phase 1b patient-level lipid distributions, pancreatitis or cardiovascular endpoints where feasible, off-target editing, hepatic safety, and durability.<\/p>\n

Company and Product Background<\/h4>\n

CTX310 uses LNP delivery to edit hepatic ANGPTL3, a regulator of triglyceride and LDL metabolism. CASGEVY is an ex vivo BCL11A-enhancer-edited autologous HSC therapy for sickle cell disease and transfusion-dependent beta thalassemia.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • New regulatory designation, not approval.<\/li>\n
  • The CASGEVY $99 million quarterly revenue is an observed commercial metric, while pediatric approvals cited in the update predate this report.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Meaningful regulatory progress for an in vivo editor, but direction on clinical value remains uncertain until indication-specific data and safety mature.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 3 of 5. Signal Direction: positive for process, uncertain for patient benefit. Confidence in Facts: moderate to high (company primary disclosure; regulator designation record not independently retrieved). Confidence in Interpretation: moderate to low.<\/p>\n","protected":false},"excerpt":{"rendered":"

    In a November 2 disclosure recovered in the 36-hour window, CRISPR Therapeutics said FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310 for severe hypertriglyceridemia and elevated LDL-C. The company also reported third-quarter…<\/p>\n","protected":false},"author":1,"featured_media":4055,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1344,269,193,1342,1343],"class_list":["post-4049","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-angptl3","tag-base-editing","tag-crispr-therapeutics","tag-ctx310","tag-rmat"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4049","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4049"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4049\/revisions"}],"predecessor-version":[{"id":4059,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4049\/revisions\/4059"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4055"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4049"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4049"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}